Immunotherapy before surgery may help remove stubborn colon cancer

NCT ID NCT06215677

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This trial tests whether giving the immunotherapy drug camrelizumab before surgery can help completely remove T4 colon cancers that have a specific genetic feature (dMMR). These cancers often don't respond well to standard chemotherapy. The study will enroll 18 adults who will receive three doses of camrelizumab, then undergo surgery 2-3 weeks later. The main goal is to see if the cancer can be removed with clear margins and without damaging nearby organs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Camrelizumab (an immunotherapy drug)
What this could lead to
If successful, this could show that immunotherapy before surgery helps remove all cancer while sparing nearby organs in patients with this specific colon cancer type.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peking Union Medical College Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.